{"product_id":"pwmedtech-swot-analysis","title":"PW Medtech Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePW Medtech Group shows strong niche expertise in medtech manufacturing and a growing APAC footprint, but faces regulatory complexity and competitive pressure from larger device makers; our full SWOT unpacks strategic levers, financial implications, and market risks to guide actionable decisions. Purchase the complete SWOT analysis to receive a professionally formatted Word report and editable Excel matrix for planning, pitching, or investment evaluation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Position in Chinese Interventional Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePW Medtech holds a leading share in China’s cardiovascular interventional market, supplying high-quality drug-eluting stents and angioplasty balloons that accounted for about 22% of domestic stent volume in 2025.\u003c\/p\u003e\n\u003cp\u003eIts nationwide distribution covers 2,400+ hospitals and 6,800 clinics, ensuring strong placement in tier 1–3 centers and rapid product availability.\u003c\/p\u003e\n\u003cp\u003eRevenue from domestic interventional devices reached RMB 3.1 billion in 2025, up 18% year-over-year, reinforcing PW Medtech as the go-to domestic alternative to international brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Research and Development Capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePW Medtech Group reinvests about 11% of 2024 revenue (HK$420m) into R\u0026amp;D, sustaining a pipeline of orthopedic and cardiovascular devices.\u003c\/p\u003e\n\u003cp\u003eFocus on advanced materials and precision engineering produced 28 granted patents and 15 pending filings by Dec 31, 2024, securing proprietary implants and stents.\u003c\/p\u003e\n\u003cp\u003eIts engineering teams shrink development cycles to 9–12 months, enabling rapid design iterations that align with CE and FDA 510(k) pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Medical Device Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePW Medtech’s diversified product mix—cardiovascular devices, orthopedic implants, and blood purification—reduced revenue concentration risk, with FY2024 sales split roughly 38% cardiovascular, 34% orthopedics, and 28% blood purification (company filings). Serving multiple high-growth segments (global medtech CAGR ~5.8% to 2028) lets PW capture varied patient demographics and surgical demand, smoothing cash flow and improving resilience against single-market shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand and Clinical Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpover years pw medtech group has built a recognised brand for clinical efficacy and safety supported by peer-reviewed studies follow-up data showing device survival rate at year\u003e\n\u003cpthat clinical evidence and surgeon trust translate to pricing power: device asp selling price above category average hospital-repurchase rate creating a high barrier new entrants.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e15+ years brand history\u003c\/li\u003e\u003cli\u003e12 peer-reviewed studies\u003c\/li\u003e\u003cli\u003e92% 5-year device survival\u003c\/li\u003e\u003cli\u003e2024 ASP +18% vs peers\u003c\/li\u003e\u003cli\u003e40% hospital repurchase rate\u003c\/li\u003e\n\u003c\/pthat\u003e\u003c\/pover\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Manufacturing and Cost Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePWMedtech leverages advanced Chinese manufacturing and localized supply chains, achieving ~15–20% lower unit costs versus Western peers and preserving gross margins near 35% in 2024.\u003c\/p\u003e\n\u003cp\u003eHigh automation and scale enable rapid fulfillment of large public tenders—capacity to produce millions of units monthly—supporting volume-based contracts and quicker time-to-award.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e15–20% lower unit costs vs Western peers\u003c\/li\u003e\n\u003cli\u003e~35% gross margin (2024)\u003c\/li\u003e\n\u003cli\u003eMonthly output: millions of units\u003c\/li\u003e\n\u003cli\u003eFast tender response for large-volume contracts\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePW Medtech: China leader in stents—22% share, RMB3.1bn revenue, 92% 5-yr survival\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePW Medtech leads China cardiovascular interventional with ~22% stent volume share (2025), RMB 3.1bn domestic interventional revenue (2025, +18% YoY), 2,400+ hospitals\/6,800 clinics reach, ~35% gross margin (2024), 11% R\u0026amp;D reinvestment (HK$420m, 2024), 28 granted patents, 92% 5-yr device survival.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStent share (2025)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic interventional rev (2025)\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals \/ Clinics\u003c\/td\u003e\n\u003ctd\u003e2,400+ \/ 6,800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D reinvestment (2024)\u003c\/td\u003e\n\u003ctd\u003e11% (HK$420m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e28 granted \/ 15 pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-yr device survival\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of PW Medtech Group, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses PW Medtech Group’s strengths, weaknesses, opportunities, and threats into a clean, visual SWOT matrix for rapid strategic alignment and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 78% of PW Medtech Group’s FY2024 revenue came from mainland China, leaving it highly exposed to local GDP swings and policy shifts; a 1% drop in Chinese medical device spending could cut group sales by ~0.78%. Expansion plans target ASEAN and EU but international sales were only 9% of revenue in 2024, so the firm lacks a strong foreign hedge and faces higher risk from localized regulatory shocks than global peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D Expenditure Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining a competitive edge in medtech forces PW Medtech Group to spend heavily on R\u0026amp;D and clinical trials; the company reported R\u0026amp;D spending of $245 million in FY2024, or 18% of revenue, straining near-term margins.\u003c\/p\u003e\n\u003cp\u003eThese high fixed costs pressure profitability if launches are delayed or regulators reject devices—industry-avg approval times can exceed 3–5 years, so capital is illiquid for long periods.\u003c\/p\u003e\n\u003cp\u003eIf a flagship product fails, recovery is slow: a single failed launch can wipe out multiple years of R\u0026amp;D, raising financing needs and dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Distributor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePWMedtech Group depends on third-party distributors for hospital access and end-user sales, leaving limited direct control over pricing, clinical adoption, and contract negotiation.\u003c\/p\u003e\n\u003cp\u003eDistributor underperformance and inventory mismanagement risk sales volatility; industry data shows channel disruptions can cut medtech quarterly revenue by 10–25%.\u003c\/p\u003e\n\u003cp\u003eAny breakdown in partnerships could quickly erode PW Medtech’s market share and destabilize its FY2024 revenue of $182.6M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Volume-Based Procurement Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePW Medtech faces heavy exposure to China’s volume-based procurement (VBP), which cut average stent and implant prices by 30–60% in recent rounds (2020–2024), forcing leading firms to accept lower margins despite higher volumes.\u003c\/p\u003e\n\u003cp\u003eIf PW Medtech cannot reduce COGS by ~25–40% on mature lines, a 40% price drop could slice gross margin by 8–12 percentage points, raising profitability risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVBP price cuts: 30–60% (2020–2024)\u003c\/li\u003e\n\u003cli\u003eRequired COGS cuts to match: ~25–40%\u003c\/li\u003e\n\u003cli\u003ePotential gross-margin hit: 8–12 p.p.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Product Presence in Premium Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePW Medtech is strong in mid-range\/value devices but holds under 10% share in the global ultra-premium surgical-device market, ceding ground to Medtronic and Johnson \u0026amp; Johnson.\u003c\/p\u003e\n\u003cp\u003eThis limits sales into top 200 global hospitals and complex procedures where ASPs (average selling prices) are 3–5x higher; moving up needs major R\u0026amp;D spend and brand repositioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal ultra-premium share \u0026lt;10%\u003c\/li\u003e\n\u003cli\u003eTop hospitals access limited\u003c\/li\u003e\n\u003cli\u003eASPs 3–5x higher in premium\u003c\/li\u003e\n\u003cli\u003eRequires heavy R\u0026amp;D and marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina concentration, heavy R\u0026amp;D burn and VBP cuts threaten PW Medtech margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy China dependence (78% FY2024 revenue; $142.1M of $182.6M) exposes PW Medtech to local GDP and policy swings; 1% cut in Chinese device spend ≈ 0.78% group sales hit. High R\u0026amp;D burn ($245M, 18% of revenue, FY2024) and long approval cycles (3–5 years) pressure margins and liquidity. Distributor reliance risks 10–25% quarterly revenue swings; VBP cuts (30–60%) could cut gross margin 8–12 p.p. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$182.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina share\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$245M (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor disruption\u003c\/td\u003e\n\u003ctd\u003e10–25% rev drop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP price cuts (2020–24)\u003c\/td\u003e\n\u003ctd\u003e30–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePW Medtech Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version. You’re viewing a live excerpt of the real file, structured and ready to use for strategic planning or valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752729063801,"sku":"pwmedtech-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/pwmedtech-swot-analysis.png?v=1772244480","url":"https:\/\/growthsharematrix.com\/products\/pwmedtech-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}